World Antibiotics Market

http://www.reportlinker.com/p092489/World-Antibiotics-Market.html

This report analyzes the worldwide markets for Antibiotics in US$ Billion. The Major product segments Analyzed are Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 204 companies including many key and niche players worldwide such as Abbott Laboratories, MiddleBrook(TM) Pharmaceuticals, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook(TM) Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., Toyama Chemical Co., Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTIBIOTICS MCP-1705A GLOBAL STRATEGIC BUSINESS REPORTCONTENTSI. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-2Quantitative Techniques & Analytics I-2Product Definitions and Scope of Study I-3Penicillin I-3Cephalosporins I-4Macrolides I-4Quinolones I-4Carbapenems I-4Other Antibiotics I-4Aminoglycosides I-4Tetracyclines I-4Sulfonamides I-4Mupirocin I-5Glycopeptides I-5Synercid I-5Oxazolidinones I-5Linezolid I-5II. EXECUTIVE SUMMARY1. Industry Overview II-1Antibiotic Resistance and Generic Competition to Impact LongTerm Growth II-1Current & Future Analysis II-12. Market Dynamics II-2Anti-Bacterials Segment Drives Global Anti-Infectives Market II-2Antibiotic Resistance - A Primary Growth Inhibitor II-2Antibiotic-Resistant Bacteria by Type II-2Patent Expiries Commoditize Antibiotics II-3Patent Expiries of Leading Drugs in the Recent Past, Current,and Future II-3Anti-MRSA Antibiotics Find Their Way . II-3Table 1: Estimated Revenues Generated by Leading MRSAAntibiotic Drugs in 2005 (includes corresponding Graph/Chart) II-4Key Antibiotics in Pipeline II-43. Competition II-5Highly Competitive Market II-5Table 2: Leading Players in the Worldwide Antibiotics Market(2006): Percentage Breakdown by Value Sales for Pfizer, GlaxoSmithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott,Wyeth, and Others (includes corresponding Graph/Chart) II-5GlaxoSmithKline - The Undisputed Leader of Penicillin Market II-5Table 3: Worldwide Leading Antibiotics within PenicillinClass (2005 & 2006): Percentage Breakdown by Value forAugmentin, Zosyn/Tazocin, Amoxil, and Others (includescorresponding Graph/Chart) II-6GlaxoSmithKline Leads Cephalosporin Market II-6Table 4: Worldwide Leading Antibiotics within CephalosporinClass (2005 & 2006): Percentage Breakdown by Value forRocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil,Cefzon, Flumarin, and Others (includes correspondingGraph/Chart) II-6Pfizer Dominates Macrolides Market II-7Table 5: Worldwide Leading Antibiotics within Macrolide Class(2005 & 2006): Percentage Breakdown by Value for Zithromax,Klaricid/Biaxin, Ketek, and Others (includes correspondingGraph/Chart) II-7Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic II-7Table 6: Worldwide Leading Antibiotics within Quinolone Class(2005 & 2006): Percentage Breakdown by Value forLevaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, andOthers (includes corresponding Graph/Chart) II-7Merck Rules Carbapenems Market II-8Table 7: Worldwide Leading Antibiotics within CarbapenemClass (2005 & 2006): Percentage Breakdown by Value forPrimaxin, Merrem, Invanz, and Others (includes correspondingGraph/Chart) II-84. Product Overview II-9Antibiotics - An Introduction II-9Antibiotic Resistance II-9� -Lactams II-10Classification of Antibiotics II-11Key Milestones in Antibiotic Development II-11Antibiotic Types II-11Penicillin II-11History II-11About the Drug II-12Cephalosporins II-12Treatment II-12Effects of the Drug II-13Macrolides II-13Treatment II-13Quinolones II-13Carbapenems II-14Other Antibiotics II-14Aminoglycosides II-14Treatment II-14Effects of the Drug II-15Tetracyclines II-15Treatment II-15Effects of the Drug II-16Sulfonamides II-16Treatment II-16Effects of the Drug II-17Mupirocin II-17Glycopeptides II-17Synercid II-17Oxazolidinones II-18Linezolid II-185. Research Findings II-19Cephalosporins Effective when Compared to Penicillin II-19FDA Bans Baytril Antibiotic for Chickens II-19Erythromycin Along with Some Specific Drugs Increase Risk ofSudden Death II-19Rise in Usage of Quinolones for Urinary Tract Infections Leadsto Drug Resistance II-196. FDA Approvals/Patents II-20MiddleBrook Obtains NDA Approval for MOXATAG(TM) II-20J&JPRD Seeks FDA Approval for Doripenem Antibiotic II-20J&JPRD Seeks FDA Approval for Investigational Antibiotic,Ceftobiprole II-20GSK Receives Approval for ALTARGO® in Europe II-20APL Receives FDA Approval for Cefpodoxime Proxetil II-21Cubist Receives Approval to Market CUBICIN in Canada II-21Cubist Obtains Approval to Market CUBICIN for AddedIndications in EU II-21Cubist Gains Approval for CUBICIN in Taiwan and South Korea II-21Cethromycin Achieves FDA's Orphan Drug Designation II-21FDA Approves Wockhardt's Cefotaxime Injection II-22FDA Approves Doxycycline Tablets II-22FDA Approves Clarithromycin II-22FDA Approves Doxycycline Tablets For The US Market II-22Johnson & Johnson Applies Doripenem For FDA Approval II-22FDA Certifies Antibioticos do Brasil's Plant II-22FDA Certifies ANDA For Cefdinir Capsules II-22US FDA Approves Teva's Cefprozil Tablets II-23FDA Certifies ANDA for Cephalexin Capsules II-23American Pharmaceutical Partners Receives FDA Approvals forCeftriaxone for Injection, USP II-23Advancis's Keflex Receives FDA Approval II-23Wockhardt Gains Marketing Approval for Cefuroxime axetil inthe US II-23Wyeth's Mylotarq Receives Government's Approval II-23FDA Approves Generic Version of Zithromax II-24Pfizer Wins FDA Approval for Zmax(TM) II-24Venus Remedies Files Second PCT for New Cephalosporins II-24Falcon Gains US FDA Approval for its Generic Anti-InfectiveSolution II-24Cadilla Receives FDA Approval to Market Clindamycin II-257. Recent Industry Activity II-263i to Buy Alpharma Unit II-26NCPC to Acquire Stake in DSM's Antibiotics Division II-26ULL Establishes New Antibiotics Unit in Himachal Pradesh II-26Biocat to Expand Presence in the Indian Market II-26PRWT Acquires Cherokee Chemical Unit from Merck II-26CSPC Joins Hands with Indonesian Firms II-27Nisshin-Kyorin to Merge with Kyorin Pharmaceutical II-27Schering-Plough Acquires Organon BioSciences II-27GSK & Anacor Partner for Boron Chemistry-Based Antibioticsand Antivirals II-27Iroko Bags Canadian Rights to Vancocin® II-28Cubist Licenses CUBICIN Rights to Merck II-28Sagent Partners with Astral to Develop Injectable Antibiotics II-28MR Healthcare to Manufacture New Antibiotics & Medicines II-28Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo II-29C&O Pharmaceutical to Distribute Meiact in China II-29Bioton Signs Deal to Market Antibiotics in Russia II-29Toyama Gains Marketing Approval for Geninax® in Japan II-29Forest Laboratories Acquires Cerexa II-29Oscient Modifies Licensing Agreement With LG Life Sciences II-29Orchid Sign Licensing & Distribution Pact With Actavis II-30Forest Laboratories Revokes Partnership With Replidyne II-30SRI and Blanca Collaborate To Develop & Test Carbacephem II-30AstraZeneca To Expand Research Center For Antibiotics II-30Jade Pharmaceutical Begins Levofloxacin's Production in China II-30Reyoung To Start Antibiotic Production At New Facility II-31Toyama Begins T-705 Clinical Trials II-31SmPC For Sanofi-Aventis' Ketek® Updated II-31Lupin Receives Approval for Cefpodoxime Proxetil AntiobioticTablets in France II-31Antibiotice Plans To Infuse Funds For Antibiotics Production II-31UAE Approves Pfizer's Zithromax SD II-31Premier Takes Over Cereplex II-31Laboratorios Roemmers Acquires Argentine Pharmaceutical'sBusiness II-32Ranbaxy Adds Be-Tabs II-32AstraZeneca Purchases Vancocin® From Eli Lilly II-32Ranbaxy Laboratories Limited Acquires Ethimed NV II-32Ranbaxy Laboratories Limited Acquires Terapia SA II-32Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline II-33Connetics Acquires Sales Organization of PediaMed II-33Wyeth Increases Stake in Wyeth KK to 80% II-33Sankyo Pharma, Daiichi Medical Research and DaiichiPharmaceutical Merge II-34Merck & Co. and Paratek Sign Development & License Pact II-34Wakunga and Rib-X Sign Licensing Pact II-34Pfizer Settles Infringement Lawsuit With Teva II-34Astellas Extends Agreement With Theravance II-34Astellas and Theravance Sign Collaboration Agreement II-35Cubist and AstraZeneca Sign License Pact II-35Astellas Pharma and Sanofi-Aventis Revoke Marketing Pact II-35Achaogen Bags Licensing Agreement from Isis II-35Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico II-35Replidyne Enters into Licensing Agreement with ForestLaboratories II-35Toyama Chemical Co Ltd Enters into Licensing Agreement withAstellas Pharma II-36AVAS' Majority Stake To Be Sold II-36NIH Grants US$3 Million To PolyMedix For Antibiotics II-36Wyeth's Tygacil Achieves European Approval II-36Chiron's Cubicin® Receives Marketing Grant In The EU II-37Vietnam Bans Antibiotics In Aquaculture II-37Sance Pharmaceuticals Establishes Sance Laboratories II-37Caps Holdings Plans to Re-enter Penicillin Market II-37Alkem Establishes Sterile Cephalosporin Unit II-37Novartis Completes Chiron Acquisition II-37Toyama Submits New Drug Application For Quinolone AntibioticCompound II-37China Pharma Receives GMP Certification For CephalosporinAntibiotic Production II-38Venus Remedies Files For FDC Approval II-38Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion II-38Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma II-38Pfizer Acquires Idun Pharmaceuticals II-38Pfizer Acquires Vicuron Pharmaceuticals II-39Pfizer Acquires Bioren II-39Novartis Acquires Eon Labs II-39Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar II-40Targanta Acquires InterMune's Late-Stage Antibiotic II-40Novartis Acquires Hexal II-40TB Alliance and Bayer Partner in Clinical Trials II-41SBC Communications Enters into Agreement with Pfizer forManaged Voice Services II-41Vicuron Extends Oral Antibiotics Development Agreement WithPfizer II-42Orchid Chemicals Signs Distribution Agreement with Mayne Pharma II-42Cubist Pharmaceuticals Inks Agreement with ACS Dobfar II-42Orchid Chemicals Inks Marketing Agreement with Alpharma II-42Lupin and DSM Anti-Infectives Sign Agreement to MarketCephalosporins II-42Ranbaxy to Market P&G's Generic Drug II-43Nectar Expands Capacity II-43Novartis Establishes Novartis Holding Japan II-43Sun Pharma Acquires Phlox Pharma II-43Kyorin Takes Over ActivX II-43Advancis Acquires Lilly's Keflex Brand II-43Enanta Enters into Partnership with Shionogi & Co. II-44Toyama Signs Collaborative Agreement with Glaxo to DevelopAntibacterial Agents II-44Enanta and Shionogi Ink an Agreement to Market EP- 013420 II-45Orchid Inks Agreement with Apotex to Market Generic Antibiotics II-45Toyama Signs Licensing Agreement for TN-3262a with Dong-A II-45Toyama Inks License Agreement with Schering for T-3811 II-45Shionogi Wins Rights to Market Cedax in the US II-46Connetics Enters Acne Market II-468. Product Innovations/Introductions II-47MIT Scientists Develop a New Antibiotic, Rhodostreptomycin II-47Watson Pharma Introduces Biaxin XL's Generic Version II-47Toyama Launches New Garenoxacin Quinolone Antibiotic II-47Wockhardt to Introduce Cefprozil in the US II-47MSD India Launches Invanza in India II-47Orchid Chemicals to Introduce Three New Drugs in the US II-48DUSA Pharmaceuticals Releases ClindaReach(TM) II-48Mylan Releases Cipro's Generic Version II-48Macrolide Antibiotic Developed In the US II-48University of Michigan Devises NMR Spectroscopy For Antibiotics II-48Glycopeptide-Cephalosporin Antibiotics Developed In The US II-48Neosil Tests NEO 101 Antibiotic II-48New Antibiotic Developed By Canadian Inventors II-49Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada II-49Pencillin Binding Protein Found In Japan II-49Venus Remedies Releases Mucomelt-Forte II-49Baxter Launches Injectable Antibiotic, Zithromax II-49Advancis Releases Keflex (750mg) Capsules II-49Researchers Develop Antibiotic For MRSA II-50Wyeth Releases Tygacil In The UK II-50Nihon Pharmaceutical Releases Clarithomycin Antibiotic II-50Daiichi Sankyo Engages In Quinolone Antibiotic Development II-50Shionogi Commercializes Finibax II-50Sandoz and Nomura Phase4 Ventures Launch Nabriva TherapeuticsForschungs GmbH II-50Lilly's Investigational Cancer Agent Reaches Phase IIIClinical Trial II-50Idemitsu Technofine Launches Antibacterial Product II-51Galleon Develops Oral Aminoglycoside Antibiotic II-51Advancis Introduces Keflex® Powder in the US II-51Skin Test for Penicillin Comes Back into the Market II-51Cubist Introduces New Registry Program II-52Idemitsu Technofine Launches Antibacterial Product II-529. Focus on Select Global Players II-53Abbott Laboratories (USA) II-53MiddleBrook(TM) Pharmaceuticals, Inc. (USA) II-53Bayer HealthCare AG (Germany) II-53Bristol-Myers Squibb Co. (USA) II-54Cubist Pharmaceuticals, Inc. (USA) II-54Daiichi Sankyo Company, Limited (Japan) II-54Eli Lilly and Co. (USA) II-55GlaxoSmithKline Plc (UK) II-56Johnson & Johnson (USA) II-56Kyorin Pharmaceutical Co., Ltd. (Japan) II-57LG Life Sciences Limited (Korea) II-57MiddleBrook(TM) Pharmaceuticals, Inc. (USA) II-58Novartis AG (Switzerland) II-58Pfizer Inc. (USA) II-59Pliva d.d. (Croatia) II-59Roche (Switzerland) II-60Sanofi-Aventis SA (France) II-60Takeda Pharmaceutical Company, Ltd. (Japan) II-60Toyama Chemical Co., Ltd. (Japan) II-61Wyeth Pharmaceuticals, Inc. (USA) II-6110. Global Market Perspective II-63Table 8: World Recent Past, Current & Future Analysis forAntibiotics by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of World MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart) II-63Table 9: World Long-term Projections for Antibiotics byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-64Table 10: World 10-Year Perspective for Antibiotics byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan),and Rest of World Markets for Years 2003, 2008 & 2012(includes corresponding Graph/Chart) II-65Table 11: World Recent Past, Current & Future Analysis forPenicillin by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of World MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart) II-66Table 12: World Long-term Projections for Penicillin byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-67Table 13: World 10-Year Perspective for Penicillin byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-68Table 14: World Recent Past, Current & Future Analysis forCephalosporin by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) II-69Table 15: World Long-term Projections for Cephalosporin byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-70Table 16: World 10-Year Perspective for Cephalosporin byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-71Table 17: World Recent Past, Current & Future Analysis forMacrolides by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of World MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart) II-72Table 18: World Long-term Projections for Macrolides byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-73Table 19: World 10-Year Perspective for Macrolides byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-74Table 20: World Recent Past, Current & Future Analysis forQuinolones by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of World MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart) II-75Table 21: World Long-term Projections for Quinolones byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-76Table 22: World 10-Year Perspective for Quinolones byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-77Table 23: World Recent Past, Current & Future Analysis forCarbapenems by Geographic Region - US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), and Rest of World MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2000 through 2010 (includes corresponding Graph/Chart) II-78Table 24: World Long-term Projections for Carbapenems byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-79Table 25: World 10-Year Perspective for Carbapenems byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-80Table 26: World Recent Past, Current & Future Analysis forOther Antibiotics by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), and Rest of WorldMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) II-81Table 27: World Long-term Projectionsfor Other Antibiotics byGeographic Region - US, Canada, Jap an, Europe, Asia- Pacific(excluding Japan), and Rest of World Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2011through 2015 (includes corresponding Graph/Chart) II-82Table 28: World 10-Year Perspective for Other Antibiotics byGeographic Region - Percentage Breakdown of Dollar Sales forUS, Canada, Japan, Europe, Asia-Pacific (excluding Japan), andRest of World Markets for Years 2003, 2008 & 2012 (includescorresponding Graph/Chart) II-83III. MARKET1. The United States III-1A.Market Analysis III-1Current and Future Analysis III-1Antibiotics Approved Between 2000 and 2005 in the UnitedStates III-1Competition III-1Table 29: Leading Players in the US Antibiotics Market(2006): Percentage Breakdown by Value Sales for Pfizer,Johnson & Johnson, GlaxoSmithKline, Abbott, and Others(includes corresponding Graph/Chart) III-2Strategic Corporate Developments III-2Product Introductions/Innovations III-10FDA Approvals / Patents III-12Focus on Select Players III-16B.Market Analytics III-20Table 30: US Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-20Table 31: US Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarketsIndependently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-21Table 32: US 10-Year Perspective for Antibiotics by ProductSegment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-222. Canada III-23Market Analysis III-23Current And Future Analysis III-23Strategic Corporate Developments III-23Product Introductions/Innovations III-24Table 33: Canadian Recent Past, Current & Future Analysisfor Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-25Table 34: Canadian Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-26Table 35: Canadian 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-273. Japan III-28A.Market Analysis III-28Current and Future Analysis III-28Strategic Corporate Developments III-28Product Introductions/Innovations III-31Focus on Select Players III-32B.Market Analytics III-35Table 36: Japanese Recent Past, Current & Future Analysisfor Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed with AnnualSales in US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-35Table 37: Japanese Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-36Table 38: Japanese 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-374. Europe III-38A.Market Analysis III-38Current and Future Analysis III-38Strategic Corporate Developments III-38B.Market Analytics III-40Table 39: European Recent Past, Current & Future Analysisfor Antibiotics by Geographic Region - France, Germany,Italy, UK, Spain, and Rest of Europe Markets IndependentlyAnalyzed with Annual Sales in US$ Million for Years 2000through 2010 (includes corresponding Graph/Chart) III-40Table 40: European Long-term Projections for Antibiotics byGeographic Region - France, Germany, Italy, UK, Spain, andRest of Europe Markets Independently Analyzed with AnnualSales in US$ Million for Years 2011 through 2015 (includescorresponding Graph/Chart) III-41Table 41: European Recent Past, Current & Future Analysisfor Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems, and OtherAntibiotics Markets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-42Table 42: European Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems, and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-43Table 43: European 10-Year Perspective for Antibiotics byGeographic Region - Percentage Breakdown of Dollar Sales forFrance, Germany, Italy, UK, Spain, and Rest of EuropeMarkets for 2003, 2008 & 2012 (includes correspondingGraph/Chart) III-44Table 44: European 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems, and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-454a. France III-46A.Market Analysis III-46Current and Future Analysis III-46Trends III-46Over Consumption of Antibiotics - Cause of Concern III-46Strategic Corporate Developments III-47Sanofi-Aventis SA - A Key Player III-47B.Market Analytics III-48Table 45: French Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-48Table 46: French Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-49Table 47: French 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for2003, 2008 &2012 (includes corresponding Graph/Chart) III-504b. Germany III-51A.Market Analysis III-51Current and Future Analysis III-51Strategic Corporate Developments III-51Bayer HealthCare AG - A Key Player III-52B.Market Analytics III-53Table 48: German Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-53Table 49: German Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-54Table 50: German 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-554c. Italy III-56A.Market Analysis III-56Current and Future Analysis III-56Corporate Development III-56B.Market Analytics III-57Table 51: Italian Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides, Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-57Table 52: Italian Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2011 through 2015 (includes corresponding Graph/Chart) III-58Table 53: Italian 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-594d. The United Kingdom III-60Market Analysis III-60Current And Future Analysis III-60Product Introduction III-60GlaxoSmithKline Plc - A Key Player III-60Table 54: UK Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-61Table 55: UK Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin, acrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million forYears 2011 through 2015 (includes correspondingGraph/Chart) III-62Table 56: UK 10-Year Perspective for Antibiotics by ProductSegment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for2003, 2008 &2012 (includes corresponding Graph/Chart) III-634e. Spain III-64Market Analysis III-64Table 57: Spanish Recent Past, Current & Future Analysis forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2000 through 2010 (includes correspondingGraph/Chart) III-64Table 58: Spanish Long-term Projections for Antibiotics byProduct Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-65Table 59: Spanish 10-Year Perspective for Antibiotics byProduct Segment - Percentage Breakdown of Dollar Sales forPenicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-664f. Rest of Europe III-67A.Market Analysis III-67Current and Future Analysis III-67Strategic Corporate Developments III-67Product Launch III-69Focus on Select Players III-69B.Market Analytics III-71Table 60: Rest of Europe Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-71Table 61: Rest of Europe Long-term Projections forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-72Table 62: Rest of Europe 10-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown of Dollar Salesfor Penicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-735. Asia-Pacific III-74A.Market Analysis III-74Current and Future Analysis III-74India III-74Rising Prices of Penicillin G to Affect AntibioticsProduction III-74Strategic Corporate Developments III-74Product Introduction III-79FDA Approvals / Patents III-79Focus on Select Players III-79B.Market Analytics III-81Table 63: Asia-Pacific Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-81Table 64: Asia-Pacific Long-term Projections for Antibioticsby Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-82Table 65: Asia-Pacific 10-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown of Dollar Salesfor Penicillin, Cephalosporin, Macrolides, Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-836. Rest of World III-84A.Market Analysis III-84Current and Future Analysis III-84Strategic Corporate Developments III-84B.Market Analytics III-85Table 66: Rest of World Recent Past, Current & FutureAnalysis for Antibiotics by Product Segment - Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and OtherAntibiotics Markets Independently Analyzed with Annual Salesin US$ Million for Years 2000 through 2010 (includescorresponding Graph/Chart) III-85Table 67: Rest of World Long-term Projections forAntibiotics by Product Segment - Penicillin, Cephalosporin,Macrolides,Quinolones, Carbapenems and Other AntibioticsMarkets Independently Analyzed with Annual Sales in US$Million for Years 2011 through 2015 (includes correspondingGraph/Chart) III-86Table 68: Rest of World 10-Year Perspective for Antibioticsby Product Segment - Percentage Breakdown of Dollar Salesfor Penicillin, Cephalosporin, Macrolides,Quinolones,Carbapenems and Other Antibiotics Markets for 2003, 2008 &2012 (includes corresponding Graph/Chart) III-87IV. COMPETITIVE LANDSCAPETo order this report:

World Antibiotics Market

http://www.reportlinker.com/p092489/World-Antibiotics-Market.html

More market research reports here!

Contacts:Reportlinker.comNicolasUS: (805) 652-2626 or Int: +1-805-652-2626Email: nbo@reportlinker.com